Can CM272, a dual G9a/DNMT1 inhibitor, be used as an immunomodulating agent to enhance the efficacy of existing immunotherapies in melanoma?

Research output: Unpublished contribution to conferencePoster

1 Downloads (Pure)
Original languageEnglish
Publication statusUnpublished - 2019
EventBACR: novel combination strategies for cancer treatment - Antwerp, Belgium
Duration: 1 Feb 2019 → …

Conference

ConferenceBACR: novel combination strategies for cancer treatment
CountryBelgium
CityAntwerp
Period1/02/19 → …

Cite this